Axsome Therapeutics Inc (AXSM) - News Archive

In its recent announcements, Axsome Therapeutics has showcased significant progress in the clinical development of AXS-05, its investigational treatment for agitation associated with Alzheimer’s disease. The completion...

Innovative Frontiers: Axsome Therapeutics’ Advancements in Treating Central Nervous System Disorders This article discusses the recent advancements announced by Axsome Therapeutics in targeting central nervous system (C...

In a significant leap forward in the quest for effective migraine treatments, Axsome Therapeutics has announced the FDA s acceptance of their New Drug Application (NDA) resubmission for AXS-07, a promising candidate for...

Axsome Therapeutics Expands Its Clinical Trials for Solriamfetol, a Potential Breakthrough in CNS Disorder TreatmentsIn two recent announcements, Axsome Therapeutics, a leading biopharmaceutical company specializing in...

Narcolepsy is a chronic neurological disorder characterized by excessive daytime sleepiness (EDS) and a dysregulation of the sleep-wake cycle, often accompanied by sudden muscle weakness or paralysis known as cataplexy....

Axsome Therapeutics, a renowned biopharmaceutical company focused on advancing cutting-edge therapies to address central nervous system disorders, is set to revolutionize the treatment landscape for Major Depressive Dis...

The preliminary financial report reveals that Axsome Therapeutics generated $71 million in net product revenue during the fourth quarter of 2023, while the net revenue for the full year amounted to $204 million. Althoug...